The U.S. Food and Drug Administration (FDA) has qualified AIM-NASH, the first AI-based tool designed to assist doctors in evaluating metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, for use in drug development programs. The cloud-based system analyzes liver biopsy images to assess fat buildup, inflammation, and scarring, enabling faster and more standardized evaluations.
Currently, liver biopsies require multiple expert reviews, a process that is time-consuming and sometimes inconsistent. AIM-NASH provides AI-generated scores that physicians can review, streamlining clinical trials and potentially reducing the time and cost to bring new MASH treatments to patients. Studies have shown AIM-NASH assessments are comparable to evaluations performed by individual experts.
With FDA qualification, AIM-NASH is now publicly available for drug developers, supporting broader adoption of AI in clinical trials. Experts predict AI tools like AIM-NASH could cut development timelines and costs for liver disease therapies by up to 50% within three to five years.
About AIM-NASH: AIM-NASH is an AI-powered, cloud-based platform designed to analyze liver biopsies and support clinical decision-making in drug development for metabolic liver diseases.
PathAI, a global leader in AI-powered pathology, announced that the U.S. Food and Drug Administration (FDA) has qualified AIM-MASH AI Assist through the Drug Development Tool (DDT) Biomarker Qualification Program for use in metabolic dysfunction–associated steatohepatitis (MASH) clinical trials. AIM-MASH AI Assist, formerly known as AIM-NASH, is the first AI-powered pathology tool to receive FDA qualification, following its earlier European Medicines Agency (EMA) CHMP qualification.
This milestone offers a standardized, efficient, and reproducible approach for evaluating liver biopsies, supporting both patient enrollment and endpoint assessments in global MASH trials. By streamlining biopsy interpretation, AIM-MASH AI Assist can accelerate the development of new treatments for this severe liver condition.
The FDA DDT program allows qualified biomarkers to be used in investigational new drug (IND), new drug (NDA), and biologics license (BLA) applications without resubmitting validation data, enabling faster trial execution. AIM-MASH AI Assist supports a single pathologist in providing highly reproducible, consensus-level biopsy assessments, addressing a key challenge in MASH clinical trials.
“Dual qualification by the EMA and FDA provides sponsors with a regulator-approved path to use AI-assisted histology in Phase 2 and 3 MASH trials, improving consistency, reproducibility, and confidence in histologic endpoints,” said Naim Alkhouri, MD, FAASLD.
Validation studies demonstrated that AIM-MASH AI Assist matches or exceeds manual pathologist performance for fibrosis, steatosis, ballooning, and inflammation assessments, while delivering superior reproducibility across all metrics tested.
“We are proud to achieve the first FDA and EMA qualification of an AI-based biomarker,” said Andy Beck, MD, PhD, Co-founder & CEO of PathAI. “This recognition underscores our commitment to rigorous validation and responsible AI deployment to transform pathology and improve patient outcomes.”
Key Highlights of AIM-MASH AI Assist:
- First AI-powered pathology tool qualified by both FDA and EMA for MASH clinical trials.
- Enables single-pathologist scoring with consensus-level accuracy and reproducibility.
- Fully validated with over 1,400 clinical trial biopsies.
- Supports efficient Phase 2 and Phase 3 trial enrollment and endpoint assessment.
- Secure deployment via the AISight® Clinical Trials Platform in a GCP/GCLP-compliant environment.
About PathAI
PathAI provides AI-powered pathology solutions to enhance histology accuracy and accelerate drug development. Its platform leverages advanced artificial intelligence to analyze pathology images, supporting pathologists, researchers, and pharmaceutical companies. Headquartered in Boston, MA. For more information, visit www.pathai.com or follow PathAI on LinkedIn.
Sources:
1. FDA Qualifies First AI Drug Development Tool, Will Be Used in ‘MASH’ Clinical Trials; https://www.fda.gov/drugs/drug-safety-and-availability/fda-qualifies-first-ai-drug-development-tool-will-be-used-mash-clinical-trials
2. PathAI’s AIM-MASH AI Assist Becomes First AI-Powered Tool to Receive FDA Qualification for MASH Clinical Trials; https://www.pathai.com/news/pathais-aim-mash-ai-assist-becomes-first-ai-powered-pathology-tool-to-receive-fda-qualification-for-mash-clinical-trials
By